SXL 01

Drug Profile

SXL 01

Alternative Names: SXL01

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator SeleXel
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 16 Aug 2016 Institut Claudius Regaud plans the phase I PROSTIRNA trial for Prostate cancer (Metastatic disease, Second-line therapy or greater) in France (unspecified route) (NCT02866916)
  • 08 Aug 2016 Preclinical trials in Prostate cancer in France (Parenteral) before August 2016 (SeleXel website, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top